SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
World game at war: why some European nations have threatened a World Cup boycott 
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
VANCOUVER, British Columbia, April 26, 2018 -- Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers, announced today that David Main, President & CEO, will provide a corporate update at the upcoming 2018 Bloom Burton & Co. Healthcare Conference in Toronto on Thursday, May 3rd 2018.
Aquinox Presentation Details
Date: Thursday, May 3rd 2018
Time: 7:30 am Pacific Time / 10:30 am Eastern Time
Location: Toronto, ON – Sheraton Centre Hotel Toronto
A live audio webcast and archive of the event will be available at:
http://wsw.com/webcast/bloomburton3/aqxp/
To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will also be available on the Investor Relations page of the Aquinox website. The corporate overview being presented will be available following the presentation at www.aqxpharma.com.
About Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing novel therapeutics for chronic urological conditions marked by inflammation and pain. Aquinox's lead drug candidate, rosiptor (AQX-1125), is in Phase 3 development for the treatment of patients with interstitial cystitis/bladder pain syndrome (IC/BPS), a condition for which there are currently few FDA approved and/or effective treatment options. Aquinox is focused on leveraging its library of novel compounds that activate SHIP1 to develop therapeutics for application in inflammation, inflammatory pain, and blood cancers. For more information, please visit http://www.aqxpharma.com/.
Investor Contact Info:
Brendan Payne
Associate Director, Investor Relations
Aquinox Pharmaceuticals, Inc.
604.901.3019
[email protected]
Gitanjali Ogawa
Vice President
The Trout Group
646-378-2949
[email protected]
